Submit Manuscript  

Article Details


Establishment of Novel Cells Stably Secreting Various Human IL-18 Recombinant Proteins

[ Vol. 20 , Issue. 1 ]

Author(s):

Asuka Kumagai, Kenji Shimizu, Riho Kurata, Xiaofeng Cui, Takayuki Isagawa, Masamitsu Harada, Jun Nagai, Yasuhiro Yoshida, Kei-ichi Ozaki, Norihiko Takeda, Hiroaki Semba and Tomo Yonezawa*   Pages 47 - 55 ( 9 )

Abstract:


Background: The immunotherapies against cancer, autoinmmune diseases or infection are remarkable development. These days programmed cell death (PD)-1 antibody-induced immune checkpoint blockade or chimeric antigen receptor-T cells (CAR-T) have been shown to have eminent therapeutic effects on tumor development. We have focused on adoptive transfer with human gamma delta T cells for novel immunotherapies. Additionally, IL-18 is one of the cytokines that enhances cytokine secretion and cytotoxicity of human gamma delta T cells.

Method: Thus, we established novel cell lines stably expressing and secreting various types of human recombinant IL-18 proteins to their culture supernatants using episomal vector. We also differentiated primary cultured human gamma delta T cells from peripheral blood mononuclear leukocytes to validate biological activity of the IL-18 proteins using measuring IFN-γ by ELISA.

Results and Conclusion: Finally, we demonstrated that the supernatant could activate human gamma delta T cells using monitoring interferon gamma in culture medium.

Keywords:

IL-18, EBNA1, OriP, conditioned medium, human gamma delta T cells, IFN-γ.

Affiliation:

Center for Therapeutic Innovation, Gene Research Center for Frontiers Life Sciences, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-14 Sakamoto, Nagasaki 852-8523, Division of Immune Regulation, Institute for Genome Research, Tokushima University, Tokushima-shi, Tokushima, Education and Research Center for Fundamental Pharmaceutical Sciences, Osaka University of Pharmaceutical Sciences, Osaka, School of Chemistry, Chemical Engineering and Life Sciences, School of Materials and Engineering, Wuhan University of Technology, 122 Loushi Rd, Wuhan, Hubei, Department of Cardiovascular Medicine, Graduate School of Biomedical Sciences, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Center for Therapeutic Innovation, Gene Research Center for Frontiers Life Sciences, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-14 Sakamoto, Nagasaki 852-8523, Center for Therapeutic Innovation, Gene Research Center for Frontiers Life Sciences, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-14 Sakamoto, Nagasaki 852-8523, Department of Immunology and Parasitology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Education and Research Center for Fundamental Pharmaceutical Sciences, Osaka University of Pharmaceutical Sciences, Osaka, The University of Tokyo, Department of Cardiovascular Medicine, Graduate School of Medicine, 7- 3-1, Hongo, Tokyo, Bunkyo-ku, 113-8654, Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo, Japan Nishiazabu 3-2-19, Minato-ku, Tokyo 106-0031, Center for Therapeutic Innovation, Gene Research Center for Frontiers Life Sciences, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-14 Sakamoto, Nagasaki 852-8523

Graphical Abstract:



Read Full-Text article